TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine whether tDCS in combination with motor training can improve hand and arm function in stroke patients.


Options:
A: Arm Label: real-tDCS with MI-BCI; Type: ACTIVE_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Arm Label: sham-tDCS with MI-BCI; Type: SHAM_COMPARATOR; Interventions: Device: real-tDCS with MI-BCI | Intervention Type: DEVICE; Name: real-tDCS with MI-BCI; Assigned to Arm(s): real-tDCS with MI-BCI, sham-tDCS with MI-BCI
B: Arm Label: Real; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Arm Label: sham; Type: PLACEBO_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Intervention Type: DEVICE; Name: transcranial direct current stimulation tDCS; Assigned to Arm(s): Real, sham | Intervention Type: DEVICE; Name: transcranial magnetic stimulation TMS; Assigned to Arm(s): Real, sham
C: Arm Label: tDCS + physical therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS + physical therapy | Arm Label: Sham tDCS + physical therapy; Type: SHAM_COMPARATOR; Interventions: Device: tDCS + physical therapy | Intervention Type: DEVICE; Name: tDCS + physical therapy; Assigned to Arm(s): Sham tDCS + physical therapy, tDCS + physical therapy
D: Arm Label: Upper limb motor function training + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: upper limb motor function training + sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS) | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Upper limb motor function training + tDCS, upper limb motor function training + sham tDCS

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab
Brief Summary: This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.


Options:
A: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg
C: Arm Label: MEDI9929 280 mg; Type: EXPERIMENTAL; Interventions: Biological: MEDI9929 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI9929; Assigned to Arm(s): MEDI9929 280 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Brief Summary: This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable stage IIIB, IIIC, or IVM1a melanoma.


Options:
A: Arm Label: Imiquimod; Type: EXPERIMENTAL; Interventions: Drug: Imiquimod cream + surgery | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + surgery | Intervention Type: DRUG; Name: Imiquimod cream + surgery; Assigned to Arm(s): Imiquimod | Intervention Type: DRUG; Name: Placebo + surgery; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
C: Arm Label: Arm A (nivolumab, surgery); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm B (nivolumab, ipilimumab, surgery); Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm C (nivolumab, relatlimab, surgery); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Biological: Relatlimab, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B (nivolumab, ipilimumab, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery) | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery) | Intervention Type: BIOLOGICAL; Name: Relatlimab; Assigned to Arm(s): Arm C (nivolumab, relatlimab, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery)
D: Arm Label: Surgery; Type: OTHER; Interventions: Procedure: Immediate surgical resection of melanoma lesion(s) | Arm Label: Talimogene Laherparepvec; Type: EXPERIMENTAL; Interventions: Drug: Talimogene Laherparepvec | Intervention Type: DRUG; Name: Talimogene Laherparepvec; Assigned to Arm(s): Talimogene Laherparepvec | Intervention Type: PROCEDURE; Name: Immediate surgical resection of melanoma lesion(s); Assigned to Arm(s): Surgery

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability, Patterns of Use and Safety of Electronic Cigarette in People With Mental Illness: a Pilot Study
Brief Summary: People with mental illness are more likely to smoke and are more severely addicted to nicotine than the general population. As a result, the number of deaths related to tobacco is higher.

Smoking is highly addictive because it delivers nicotine very quickly. Research studies show that people who use nicotine replacement therapies (such us patches, gums, etc) are more likely to quit smoking than those who try to quit without using these nicotine products. Recently a new electronic nicotine delivery system (ENDS), also known as electronic cigarette (e-cigarette) is rapidly gaining popularity. Electronic cigarettes are devices that mimic traditional cigarettes and deliver nicotine but do not carry the dangerous chemicals contained in tobacco cigarettes.

Given the increasing popularity of e-cigs, there is an urgent need to improve our understanding of both the potential benefits and risks of e-cigs use in people with serious mental illness. In this pilot we propose inviting 50 people with schizophrenia (or schizophrenia-related disorder) who are not intending to quit smoking in the near future to take part in a study in which we will provide 6-weeks of free e-cigs, followed by a 4-week period in which they will not receive free e-cigs and we monitor which products participants choose, and a final 24-week follow-up visit. During the 24-week study period we will assess the use of e-cigs and tobacco cigarettes, the exposure to nicotine and tobacco toxicants, nicotine withdrawal symptoms, the changes in respiratory symptoms and psychiatric symptoms as well as the e-cigs perceived benefits and risks.


Options:
A: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
B: Arm Label: Electronic cigarettes; Type: EXPERIMENTAL; Interventions: Other: disposable electronic cigarettes | Intervention Type: OTHER; Name: disposable electronic cigarettes; Assigned to Arm(s): Electronic cigarettes
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diaphragm Release Manual Technique Efficacy on Diaphragmatic Mobility, Respiratory Muscle Strength and Exercise Performance in COPD Patients: a Randomized Controlled Trial
Brief Summary: The aims of this study are to evaluate the effects of Diaphragm Release Manual Technique on diaphragm mobility, chest wall kinematics and functional capacity of COPD patients. Methods: Randomized controlled trial (double blinded) with COPD patients, allocated in two group: intervention (IG) who will receive the Diaphragm Release manual technique on 6 non-consecutive sessions and control group (CG), who will receive a sham protocol (light touch) with the same parameters of IG. Outcomes will be evaluated as: immediate and post treatment effects (after 1 and 6 sessions respectively). The primary outcome analysed will be the diaphragm displacement (ultrasonography evaluation) and secondary outcomes will comprise abdominal and chest wall kinematics.


Options:
A: Arm Label: Inspiratory muscle training group; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training | Arm Label: Respiratory exercise group; Type: EXPERIMENTAL; Interventions: Other: Respiratory exercise | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training group | Intervention Type: OTHER; Name: Respiratory exercise; Assigned to Arm(s): Respiratory exercise group
B: Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Other: Manual Diaphragm release technique (sham) | Arm Label: Intevention Group; Type: EXPERIMENTAL; Interventions: Other: Manual Diaphragm Release Technique | Intervention Type: OTHER; Name: Manual Diaphragm Release Technique; Assigned to Arm(s): Intevention Group | Intervention Type: OTHER; Name: Manual Diaphragm release technique (sham); Assigned to Arm(s): Control Group
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Respiratory rehabilitation exercise training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Respiratory rehabilitation exercise training; Assigned to Arm(s): Experimental group
D: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: inspiratory pressure training group; Type: EXPERIMENTAL; Interventions: Device: inspiratory pressure training group | Arm Label: mixed training group; Type: EXPERIMENTAL; Interventions: Device: mixed training group | Intervention Type: DEVICE; Name: inspiratory pressure training group; Assigned to Arm(s): inspiratory pressure training group | Intervention Type: DEVICE; Name: mixed training group; Assigned to Arm(s): mixed training group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cluster-randomized Trial of a Targeted Multifaceted Intervention to Bridge the Evidence-based Gap in the Management of Acute Ischemic Stroke
Brief Summary: The purpose of this study is to evaluate whether a multifaceted quality improvement intervention can improve the adherent rate of individual and composite of evidence-based performance measures for patients with acute ischemic stroke within the first 7 days of symptom onset and reduce the incidence of a new clinical vascular event, disability, and all-cause mortality at discharge and long term clinical outcome.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COMPASS Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: COMPASS Intervention | Intervention Type: OTHER; Name: COMPASS Intervention; Assigned to Arm(s): COMPASS Intervention
B: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cluster-randomized Trial of a Targeted Multifaceted Intervention to Bridge the Evidence-based Gap in the Management of Acute Ischemic Stroke
Brief Summary: The purpose of this study is to evaluate whether a multifaceted quality improvement intervention can improve the adherent rate of individual and composite of evidence-based performance measures for patients with acute ischemic stroke within the first 7 days of symptom onset and reduce the incidence of a new clinical vascular event, disability, and all-cause mortality at discharge and long term clinical outcome.


Options:
A: Arm Label: an intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Behaviour Change Wheel model guided intervention | Arm Label: a control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behaviour Change Wheel model guided intervention; Assigned to Arm(s): an intervention arm
B: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
C: Arm Label: Enhanced complex oral health care intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced complex oral health care | Arm Label: Usual oral health care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Enhanced complex oral health care; Assigned to Arm(s): Enhanced complex oral health care intervention
D: Intervention Type: PROCEDURE; Name: structured therapeutic chain of stroke treatment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem
Brief Summary: This is a randomized clinical trial evaluating the benefits of a program that supports model care for persons with dementia and their family caregivers. Subjects were recruited from California, Nebraska and Iowa. Subjects determined to be eligible were consented and randomized into one of two groups. Two thirds of patients were enrolled into Navigated Care that provided them with assistance in meeting important benchmarks in their care, for example completion of legal and financial planning and strategies for minimizing caregiver burden. One third of patients were enrolled to a control group, entitled Survey of Care. Outcomes include quality of life, health care utilization, caregiver burden, satisfaction with care, caregiver depression, and caregiver self-efficacy.


Options:
A: Arm Label: positive affect intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Affect | Arm Label: wait list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Positive Affect; Assigned to Arm(s): positive affect intervention
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: light support, Other: 3 preventive home visits by a nurse | Arm Label: UP Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: 3 preventive home visits by a nurse | Arm Label: UP-TECH Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: Assistive Technologies, Other: 3 preventive home visits by a nurse | Intervention Type: OTHER; Name: Case Manager; Assigned to Arm(s): UP Protocol, UP-TECH Protocol | Intervention Type: OTHER; Name: Assistive Technologies; Assigned to Arm(s): UP-TECH Protocol | Intervention Type: OTHER; Name: light support; Assigned to Arm(s): Usual Care | Intervention Type: OTHER; Name: 3 preventive home visits by a nurse; Assigned to Arm(s): UP Protocol, UP-TECH Protocol, Usual Care
C: Arm Label: Navigated Care; Type: EXPERIMENTAL; Interventions: Behavioral: Navigated Care | Arm Label: Survey of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Navigated Care; Assigned to Arm(s): Navigated Care
D: Arm Label: iSupport for dementia - European-Portuguese version; Type: EXPERIMENTAL; Interventions: Behavioral: iSupport for dementia - European-Portuguese version | Arm Label: Education-only e-book; Type: ACTIVE_COMPARATOR; Interventions: Other: e-book (comparator) | Intervention Type: BEHAVIORAL; Name: iSupport for dementia - European-Portuguese version; Assigned to Arm(s): iSupport for dementia - European-Portuguese version | Intervention Type: OTHER; Name: e-book (comparator); Assigned to Arm(s): Education-only e-book

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Potentiation of the Effects of Prismatic Adaptation by Transcranial Direct Current Stimulation (tDCS) : Evaluation of Functional Interest in Negligence Rehabilitation
Brief Summary: Following stroke, over 50% of patients keep severe neurological deficiency whose unilateral neglect, mostly following a right hemispheric lesion. The prismatic adaptation involves to pointing movements toward visual targets wearing prismatic glasses. These prismatic glasses induce a shift to the right visual field for improving symptoms in short term.

Transcranial direct stimulation (tDCS) has been evaluated for different types of deficiency resulting from stroke with encouraging results. The hypothesis of the study is to evaluate the usefulness of brain stimulation as an adjunctive intervention to optimize and increase the rehabilitation of unilateral neglect to long-term.

Thus, the main objective is to evaluate the effectiveness of standard treatment with prismatic adaptation with anodal tDCS or sham tDCS.


Options:
A: Arm Label: Arm A Anodal tDCS and prismatic adaptation; Type: EXPERIMENTAL; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: Arm B: control; Type: PLACEBO_COMPARATOR; Interventions: Device: Control: placebo stimulation | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Arm A Anodal tDCS and prismatic adaptation | Intervention Type: DEVICE; Name: Control: placebo stimulation; Assigned to Arm(s): Arm B: control
B: Arm Label: Sham tDCS plus RTP; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Arm Label: Active tDCS plus RTP; Type: ACTIVE_COMPARATOR; Interventions: Device: Active tDCS | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS plus RTP | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Active tDCS plus RTP
C: Arm Label: Labyrinth training, then Standard training; Type: EXPERIMENTAL; Interventions: Device: Adaptive computer game training | Arm Label: Standard training, then Labyrinth training; Type: EXPERIMENTAL; Interventions: Device: Standard computerized training | Intervention Type: DEVICE; Name: Adaptive computer game training; Assigned to Arm(s): Labyrinth training, then Standard training | Intervention Type: DEVICE; Name: Standard computerized training; Assigned to Arm(s): Standard training, then Labyrinth training
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Behavioral: Active Intervention, Behavioral: Placebo Intervention | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Active Intervention, Behavioral: Placebo Intervention | Intervention Type: BEHAVIORAL; Name: Active Intervention; Assigned to Arm(s): Group A, Group B | Intervention Type: BEHAVIORAL; Name: Placebo Intervention; Assigned to Arm(s): Group A, Group B

Answer: A